IsoRay Ships First GliaSite(R) Brain Cancer Treatment

RICHLAND, Wash., Nov 28, 2011 (BUSINESS WIRE) -- IsoRay, Inc. ISR -4.28% announced today it has shipped its first GliaSite(R) radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite(R) radiation therapy system. The GliaSite(R) radiation therapy system is a balloon catheter device used in the treatment of brain cancer. Having already received FDA clearance, the Washington State regulatory approval opened the door for sales of IsoRay's GliaSite(R) brain cancer treatment in the United States.

IsoRay CEO Dwight Babcock says inquiries are on the rise, "News of final regulatory approval has generated a great deal of interest throughout the medical community in the U.S. and internationally. We are hearing from physicians as well as brain cancer patients who are seeking treatment options for Glioblastomas and metastasized brain cancers."

The GliaSite(R) radiation system offers an innovative alternative that presents an important advance over previous brain cancer treatments. Doctors are able to use the system to directly place a specified dosage of liquid radiation in areas where cancer is most likely to still remain after completion of brain tumor removal. The ability to precisely place a specified dosage of this form of radiation means there is less likelihood for damage to occur to healthy brain tissue compared to other alternative treatments. Importantly, the GliaSite(R) radiation treatment diminishes the ability of the tumor to recur which means important benefits for patients in longevity as well as quality of life.

source: Isoray